Hello, and welcome to the AirSculpt Technologies, Inc. First Quarter 2024 Earnings Call. [Operator Instructions] A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. It's now my pleasure to turn the call over to Dennis Dean, Chief Financial Officer. Please go ahead.

Good morning, everyone, and thanks for joining us to discuss AirSculpt Technologies results for the first quarter. Joining me on the call today is the company's Founder and Executive Chairman, Dr. Aaron Rollins; and Chief Executive Officer, Todd Magazine. Before we begin, I would like to remind you that this conference call may include forward-looking statements. These statements may include our future expectations regarding financial results and guidance, market opportunities and our growth. Risks and uncertainties that may impact these statements and could cause actual future results to differ materially from currently projected results are described in this morning's press release, and the reports we will file with the SEC, all of which can be found on our website at investors.elitebodysculpture.com. We undertake no obligation to revise or update any forward-looking statements or information except as required by law. During our call today, we will also reference certain non-GAAP financial measures. We use non-GAAP measures in some of our financial discussions as we believe they more accurately represent the true operational performance and underlying results of our business. A reconciliation of these measures can be found in our earnings release as filed this morning and in our most recent 10-Q, which will also be available on our website. With that, I'll turn the call over to Todd.

Thanks, Dennis. Good morning, everyone, and thank you for joining the call. We delivered approximately 4% revenue growth in the quarter versus the prior year. which was driven primarily by contributions from the de novo centers opened in 2023. These centers continue to outperform our internal metrics. However, we did experience some softness in our same-store centers. which was related to temporary macroeconomic headwinds, which affected a portion of our customer base that tends to be more price sensitive. The challenges we are experiencing are consistent with those highlighted by others in the aesthetic and high-end consumer retail spaces. As we noted on our last call, we saw some isolated softness exiting 2023, which carried into the first quarter. Our revenues have picked up as a result of our typical seasonal pattern, but the degree of the seasonal increase has not been up to the level we have seen in prior years. This drove overall same-store revenue down approximately 10% during the quarter. Our Q1 adjusted EBITDA was $7.3 million, which is a decline from the prior year period. As we mentioned on our last call, we anticipated the EBITDA declined both due to recent revenue trends as well as higher SG&A spending. The higher SG&A spending was a result of increases in paid search costs mostly due to increased competitive spend, as well as our higher investment in customer awareness building. As we are now in the early part of Q2, which is the height of our season, we are still tracking behind our internal revenue projections. As a result, we expect our year-over-year revenues for the quarter to be somewhat flat or slightly below prior year. Despite our recent trends, we are not making changes to our guidance at this time. That's because we are cautiously optimistic that…

Thanks, Todd. Our revenue for the quarter was $47.6 million, a 3.9% increase over the prior year quarter. Our growth was primarily due to the contribution of new de novo centers versus the prior year base. As of March 31, 2024, we operated 27 centers versus 23 at the end of the first quarter of 2023. Our same-store revenue was down 9.8% in the quarter. As Todd mentioned, we attributed the softness to weaker-than-expected performance across the broader aesthetics and consumer retail landscape, particularly related to customers that are more price sensitive. While we are seeing similar trends in the second quarter, we expect to see some improvement as we move through our later seasonal months and into the second-half of 2024. Our average revenue per case for the quarter was 12,712 and a 1% increase over the prior year's quarter. And our percentage of patients using financing to pay for procedures was approximately 50%, which is consistent with recent quarters. As a reminder, we received full payment of all procedures upfront and we do not have any recourse related to patients, who finance their procedures with third-party vendors. Our cost of service as a percentage of revenue was 37.9% versus 39.3% in the same period last year. This improvement was the result of our cost management initiatives, which continue to be a focus for us. As a reminder, we will on $2.5 million of savings for a total of $5 million and we see additional opportunities to further increase our savings in the second-half of 2024. Our customer acquisition cost for the quarter was $2,990 per case, as compared to 2,360 in the prior year. This increase, as Todd mentioned in his remarks, is due to further investments in our brand awareness activities. We expect our CAC to stay…

Thank you. We'll now be conducting a question-and-answer session. [Operator Instructions] Our first question today is coming from Josh Raskin from Devin Research. Your line is now live.

Hi, thanks. Good morning. So I understand 1Q is seasonally lower. You talked about some of the pressures. But I guess, if you look at the full-year guidance, EBITDA it implies 1Q EBITDA is only 15% of the full-year historically, first quarter has been closer to 22%. And then I hear sort of assuming cautious optimism and guidance. I guess why are you assuming cautious optimism, if we've seen softness in procedures over the last two quarters? And I guess what does guidance look like if that cautious optimism doesn't come through, right, if you sort of just run rate where we are in 2Q?

Hey Josh, it's Dennis. So yes, one of the optimistic aspects of what we're looking at really, really hinges on marketing endeavors that we've been implementing during the quarter. It's – again, it takes a while for leads to convert the cases. And we're seeing a fairly sizable uptick in our lead volumes as a result. So that gives us one portion of optimism. Our 2023 de novos are significantly outperforming where we had expected them to perform. So we're very excited about that. And we're basically using a very similar plan for the 2024 deals that are coming online. If you remember, or probably remember a year or so ago, we kind of started implementing sort of what we call a quick ramp from our de novos. And I believe that's what's accelerating these things to open up and perform better than we had originally expected. So those three things, the 2024 class all coming on in the second-half of the year, I mean, that's obviously going to drive growth differences from what we've seen in previous years.

And I guess, Dennis, embedded in that, what are your assumptions for same-store case growth maybe starting just in 2Q, but even for the full-year?

Sure, sure. So what we're looking at from that standpoint is kind of seeing a consistent case aspect for the second quarter high-single-digit decline, somewhat similar to where we finished the first quarter. We start to see that improving in the third quarter, getting close to flat and then getting towards the mid-single-digits in the fourth quarter. One of the things, if you recall, last -- in the fourth quarter of last year, we had a couple of centers that hit a pretty large hiccup in the process. And so we've done some things there, done some recruiting and those things are improving. So we think we'll be able to not have that issue. So think comp for Q4 of last year is relatively from a low standpoint. So it's a lower comp.

Okay. And then maybe just last one. Are you at the point where you're thinking about more aggressive promotion or discounting specifically just on the -- because price is holding up better, so I'm just curious, are you guys thinking about the sort of supply and demand curve and taking down the price and seeing if that increases case volume?

Hey Josh, this is Todd. I would say we're doing it very selectively and targeted. We don't want to obviously devalue the brand and go out with kind of broad price reductions. But we're very selectively and very specifically using those, and kind of retargeting in through e-mail and text offers, et cetera, et cetera. So we are doing that. I mean, we've -- as you know, we've relied heavily on the kind of buying more, save more, and that's been very beneficial for us. But we don't kind of -- we don't want to go down too much. I just think ultimately, we don't want to devalue the brand and we start bumping into other types of competitors, which I don't think really makes a lot of sense for us. So I think we want to continue to be very selective in those price discounting.

Okay, makes sense. Thanks.

Thank you. Next question today is coming from Korinne Wolfmeyer from Piper Sandler. Your live is not live.

Hey, good morning, team. Thanks for the question. I'd like to touch a little bit on the CAC and the lead generation you're seeing from this -- your increased marketing sense. The CAC was really high this quarter. At what point will that start coming down a little bit more? And then can you provide us some color on these early customer leads you're getting from all this heightened marketing spend. Just to give us a little bit of confidence that maybe once we get to the back half of the year, that case volume will improve. And how are you shifting the marketing strategy over the course of the year? Thank you.

Yes. Hey Korinne, it's Todd. So what I would say is, obviously, we believe in the business long-term, which is why we're heavily investing in lead gen. Our cost basis has definitely gone up. A lot of that is due to just competitive activity. But -- there's a few changes that we've made that seem to be really -- the early signs are very, very promising, which is what is giving us the optimism. Number one, we've kind of way -- historically, we've relied very heavily on paid search. It's been kind of the majority of our kind of lead gen efforts. We're starting to diversify away from that solely. And so we've been experimenting with connected TV, display media retargeting. In some markets, we've done some radio and outdoor. And what we're seeing actually is more organic search, which obviously is very promising for us. So ultimately, you're seeing more people come to us as opposed to us to ultimately go out and kind of buy those leads, if you will. So that's very encouraging, and we're seeing that part of it. The second is what a new initiative or kind of doubling down on an initiative, which is our -- what we call existing or aged leads. We have a lot of people kind of in our databases that obviously are interested, but have not converted. A lot of our effort over the last year or so has been put against people that are first coming in, those kind of fresh leads, we have all these leads that we can go after and try to convert. So now with some of our analytics tools, we're able to get to them a little bit more selectively, and we're seeing some very promising improvement there. And then lastly, just optimization…

One thing I would add to, Korinne, is that our cost initiatives rather than just kind of keeping those at the EBITDA level, we're kind of reinvesting back that into marketing. So that's, again, the initiatives that we've done, we just said, hey, this is a good opportunity to use these excess resources and to put back into the marketing efforts. And we expect, as we continue to identify initiatives through the year from a cost standpoint, will likely do a similar process.

Very helpful. Thank you so much for all the color. And then just to touch on the GLP-1 issue. We are seeing more offerings or more -- better accessibility for people to get GLP-1s. Do you still view that as more of an awareness driver versus demand taker for AirSculpt? Or is there any change in thinking there? Thank you.

Look, all of our research would say that GLP-1s are ultimately a tailwind for us. We're seeing a lot of patients come to us who are either interested in weight loss medication, but they -- and we've been doing a lot of marketing on this as well. The combination of weight loss medication and AirSculpt seemed to be very, very powerful. So are there some people that maybe would have come to us and they went to weight loss medications possibly, there's also a lot of people coming to us, and they discovered us because they started to investigate weight loss medications. And so ultimately, what we're seeing is a very symbiotic relationship. And it's -- so far, we're looking at it very much as an opportunity and as a tailwind as opposed to something that is a major risk. So we continue to look at it as something that's going to ultimately help us over time.

Great. Thanks so much.

Thank you. Your next question is coming from John Ransom from Raymond James. Your line is now live.

Hey, good morning. Just talking about the second quarter, this is your big quarter historically. Do you usually see this lag of a start as the quarter back-end loaded? Or are you kind of like-for-like off to a slower start versus, say, the last couple of years?

Yes. So John, I mean that -- the timing of when the quarter or when season starts is always difficult to manage. Last year, it started in March. This year, it is more of a delayed start. And so that's a little bit of a difference from a timing perspective. And so as we talked about, is the lead gen and the impact that we're seeing there, it's a little bit later in the typical season flow that we've seen in the past. So will that kind of allude to maybe a season that, kind of, moves further into the summer. Right now, we just don't know, but that's -- if the season is season for the number of months than one would suggest that would be the case.

Okay. And then secondly on marketing, let me I appreciate all the comments you're making about that. But we've been hearing for a couple of years now about how you're pivoting from the Instagram channel to something more brand awareness and celebrity endorsements. Have just looking in the rearview mirror, how would you critique your own performance in terms of that transition? And what maybe should have been done that hasn't been done so far? Thanks.

Yes. Look, it's a good question. I would say, generally, these are changes that have to be made over time. We historically have been heavily, heavily reliant on paid search is our driver. As you know, last year, we started to do some celebrity marketing, which definitely helped. We saw some definite improvements in awareness building. Well, what we saw, particularly as we were using some of these bigger celebrities is that we would get to spike and then it would kind of come back down. And as I mentioned in my prepared remarks, some of the changes that we're making now, is kind of doing this rather than kind of a couple of big celebrity relationships or partnerships over a year. How do we do this as kind of more of a string of pearl. So maybe smaller celebrities, but more frequent. And we're also finding with some of these smaller celebrities. They have a huge social following. And that's actually been very beneficial to us. So I think it's been an evolution. I think we've been moving it in the right direction. I don't think anybody would have anticipated the kind of market changes that have happened. So that, I think, has been the biggest factor. But I think generally, we were moving in the right direction. I think we're kind of now in the optimization and we're continuing to diversify our media. And I think that's proving to be very beneficial as well. So these are not changes that could happen absolutely overnight, but I think we're moving in the right direction, and we'll continue to evaluate as we make these changes, and hopefully, it will continue to drive the growth that we need.

Okay. Just lastly, I mean, we're calculating some pretty same-store numbers. Are there any locations now that are unprofitable? Do you foresee any closures or all your locations still profitable even if the volume is down.

Yes. All of our locations, John, are still generating a profit. So nothing from that standpoint. I would say the London Center is slower from a ramp standpoint as we continue to learn through that market. So it's not ramping up from a profitability standpoint like a typical center that we have, take the rest of the 2023 cohorts. It's not ramping up to the same degree as those are. But all the centers continue to be profitable. And so no reasons at all to consider closing any.

The only comment I'd make on London. I mean it's definitely -- look, international markets, particularly in Europe, I mean, there's definitely a learning curve. I think there's a lot of things that we've definitely learned, but we continue to be incredibly optimistic about the market. It just might take us a little bit longer to kind of get it all figured out. But once we do, we think that is going to be a very strong center for us.

I mean my editorial comment, the next health care company on the services side that has a good outcome in London might be -- it's been a trail of years for a lot of your peers that have been in that market. you're not alone to an editorial comment. Thank you.

Thanks, John.

Thank you. We reached the end of our question-and-answer session. I'd like to turn the floor back over to management for any further or closing comments.

Thanks, everybody. We will talk to you in a few months and have a great weekend.

Thank you. That does conclude today's teleconference. You may disconnect your lines at this time, and have a wonderful day. We thank you for your participation today.